British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

[1]  M. Leitao.  Management of epithelial ovarian cancer. , 2018, Clinical advances in hematology & oncology : H&O.

[2]  A. Reuss,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. P. Geisler,et al.  Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma: A Study of 313 Patients , 2017, American journal of clinical oncology.

[4]  A. Okamoto,et al.  Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  D. Bodurka,et al.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Kohn,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Okamoto,et al.  Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Kasamatsu,et al.  Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. , 2016, European journal of cancer.

[9]  S. Seshadri,et al.  Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. , 2016, The Cochrane database of systematic reviews.

[10]  Dianne Miller,et al.  Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. , 2016, Gynecologic oncology.

[11]  D. Gershenson.  Low-grade serous carcinoma of the ovary or peritoneum. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  D. Oram,et al.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.

[13]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[14]  D. Ahmed-Lecheheb,et al.  Ovarian cancer survivors’ quality of life: a systematic review , 2016, Journal of Cancer Survivorship.

[15]  M. Picchio,et al.  Imaging biomarkers in ovarian cancer: the role of ¹⁸F-FDG PET/CT. , 2016, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[16]  N. deSouza,et al.  Functional MR Imaging in Gynecologic Cancer. , 2016, Magnetic resonance imaging clinics of North America.

[17]  H. Kitchener,et al.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. , 2015, The Cochrane database of systematic reviews.

[18]  E. Mullins,et al.  Annual Report of the Chief Medical Officer, 2014 The Health of the 51%: Women , 2015 .

[19]  G. Lewith,et al.  Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates , 2015, BMJ Open.

[20]  J. McAlpine,et al.  Opportunistic salpingectomy for ovarian cancer prevention , 2015, Gynecologic Oncology Research and Practice.

[21]  U. Menon,et al.  Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data , 2015, International Journal of Gynecologic Cancer.

[22]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[23]  Y. Nakatani,et al.  Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. , 2015, Human pathology.

[24]  A. Tinker,et al.  Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Bryant,et al.  Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. , 2015, The Cochrane database of systematic reviews.

[26]  Matthew Burnell,et al.  Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Monk,et al.  Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Aghajanian,et al.  A systematic review of ovarian cancer and fear of recurrence , 2015, Palliative and Supportive Care.

[29]  C. Hughes,et al.  Supporting delivery of the recovery package for people living with and beyond cancer , 2014 .

[30]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary , 2014, International Journal of Gynecologic Cancer.

[31]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary , 2014, International Journal of Gynecologic Cancer.

[32]  D. Provencher,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Small Cell Cancers , 2014, International Journal of Gynecologic Cancer.

[33]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma , 2014, International Journal of Gynecologic Cancer.

[34]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas , 2014, International Journal of Gynecologic Cancer.

[35]  B. Monk,et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Cohn,et al.  Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. , 2014, Gynecologic oncology.

[37]  A. Bryant,et al.  Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. , 2014, The Cochrane database of systematic reviews.

[38]  S. Kjaer,et al.  A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population. , 2014, Gynecologic oncology.

[39]  T. Fehm,et al.  Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  W. Foulkes,et al.  No small surprise – small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour , 2014, The Journal of pathology.

[41]  D. Chambers,et al.  programmes : a rapid evidence synthesis enhanced recovery after surgery Effectiveness and implementation of Craig , 2014 .

[42]  R. Swindell,et al.  CT scan does not predict optimal debulking in stage III–IV epithelial ovarian cancer: A multicentre validation study , 2014, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[43]  M. Stockler,et al.  Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  B. Monk,et al.  Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  S. Archer,et al.  Exploring the experience of an enhanced recovery programme for gynaecological cancer patients: a qualitative study , 2014, Perioperative Medicine.

[46]  D. Katsaros,et al.  Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[47]  Jason J. Corneveaux,et al.  Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 , 2014, Nature Genetics.

[48]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Watts,et al.  Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates , 2014, BMJ Open.

[50]  J. Sehouli,et al.  HE4 Expression in Plasma Correlates with Surgical Outcome and Overall Survival in Patients with First Ovarian Cancer Relapse , 2014, Annals of Surgical Oncology.

[51]  M. Leeflang,et al.  Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. , 2014, The Cochrane database of systematic reviews.

[52]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[53]  M. Parmar,et al.  Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  T. Jobo,et al.  Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. , 2013, The Lancet. Oncology.

[55]  A. Bryant,et al.  Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. , 2013, The Cochrane database of systematic reviews.

[56]  J. Sehouli,et al.  Salvage Surgery Due To Bowel Obstruction in Advanced or Relapsed Ovarian Cancer Resulting in Short Bowel Syndrome and Long-Life Total Parenteral Nutrition: Surgical and Clinical Outcome , 2013, International Journal of Gynecologic Cancer.

[57]  T. Fehm,et al.  Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. , 2013, European journal of cancer.

[58]  M. Köbel,et al.  The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors , 2013, Modern Pathology.

[59]  J. Sehouli,et al.  Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation , 2013, Annals of Surgical Oncology.

[60]  A. Lopes,et al.  Surgical cytoreduction for recurrent epithelial ovarian cancer. , 2013, The Cochrane database of systematic reviews.

[61]  R. Zeillinger,et al.  Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. , 2013, Gynecologic oncology.

[62]  Chen Yang,et al.  Diagnostic Value of Serum Human Epididymis Protein 4 (HE4) in Ovarian Carcinoma: A Systematic Review and Meta-Analysis , 2012, International Journal of Gynecologic Cancer.

[63]  A. Al-Niaimi,et al.  Epithelial ovarian cancer. , 2012, Obstetrics and gynecology clinics of North America.

[64]  B. Davidson,et al.  Borderline ovarian tumours. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[65]  M. Gore,et al.  Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). , 2012, Gynecologic oncology.

[66]  H. Dickinson,et al.  Centralisation of services for gynaecological cancer. , 2012, The Cochrane database of systematic reviews.

[67]  J. Sampalis,et al.  Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. , 2012, The Lancet. Oncology.

[68]  K. Kwekkeboom,et al.  A systematic review of sexual concerns reported by gynecological cancer survivors. , 2012, Gynecologic oncology.

[69]  D. Miller,et al.  Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? , 2012, American journal of obstetrics and gynecology.

[70]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[71]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[72]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[73]  T. Van Gorp,et al.  Lymph node metastasis in stages I and II ovarian cancer: a review. , 2011, Gynecologic oncology.

[74]  G. Rustin,et al.  Recurrent Ovarian Cancer: When and How to Treat , 2011, Current oncology reports.

[75]  A. Brandes,et al.  Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  W. Cliby,et al.  Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. , 2011, Gynecologic oncology.

[77]  J. Berek,et al.  Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort , 2011, British Journal of Cancer.

[78]  A. Bryant,et al.  Optimal primary surgical treatment for advanced epithelial ovarian cancer. , 2011, The Cochrane database of systematic reviews.

[79]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[81]  D. Oram,et al.  Outcome of risk‐reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status , 2011, BJOG : an international journal of obstetrics and gynaecology.

[82]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[83]  J. Schorge,et al.  Carcinosarcoma of the ovary: a case-control study. , 2011, Gynecologic oncology.

[84]  J. Schorge,et al.  Recurrent Endometrial Cancer , 2011, Clinical obstetrics and gynecology.

[85]  N. Colombo.  Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study , 2011, International Journal of Gynecologic Cancer.

[86]  P. Suprasert,et al.  Mucinous Tumor of Low Malignant Potential (“Borderline” or “Atypical Proliferative” Tumor) of the Ovary: A Study of 171 Cases With the Assessment of Intraepithelial Carcinoma and Microinvasion , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[87]  C. Redman,et al.  Recognition and initial management of ovarian cancer: summary of NICE guidance , 2011, BMJ : British Medical Journal.

[88]  H. Dickinson,et al.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. , 2011, The Cochrane database of systematic reviews.

[89]  Christian Marth,et al.  2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.

[90]  S. Lele,et al.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal , 2011, Cancer.

[91]  Sabine Van Huffel,et al.  Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group , 2010, BMJ : British Medical Journal.

[92]  A. Reuss,et al.  Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO , 2010, International Journal of Gynecologic Cancer.

[93]  A. Bryant,et al.  Hormonal therapy in advanced or recurrent endometrial cancer. , 2010, The Cochrane database of systematic reviews.

[94]  Corneel Coens,et al.  Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.

[95]  H. Dickinson,et al.  Interventions for the treatment of borderline ovarian tumours. , 2010, The Cochrane database of systematic reviews.

[96]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[97]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[98]  A. Sood,et al.  Prevalence of Lymph Node Metastasis in Primary Mucinous Carcinoma of the Ovary , 2010, Obstetrics and gynecology.

[99]  H. Dickinson,et al.  Palliative surgery versus medical management for bowel obstruction in ovarian cancer. , 2010, The Cochrane database of systematic reviews.

[100]  I. Vergote,et al.  Lymph Node Sampling and Taking of Blind Biopsies Are Important Elements of the Surgical Staging of Early Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[101]  H. Dickinson,et al.  Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. , 2010, The Cochrane database of systematic reviews.

[102]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[103]  A. Reuss,et al.  Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.

[104]  A. Zwinderman,et al.  Understanding the problem of inadequately staging early ovarian cancer. , 2010, European journal of cancer.

[105]  H. Tsuda,et al.  Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[106]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  A. Reuss,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[108]  I. Fernando,et al.  Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment , 2009, International Journal of Gynecologic Cancer.

[109]  S. Loibl,et al.  Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis , 2009, Annals of Surgical Oncology.

[110]  J. Aitken,et al.  Unmet needs of gynaecological cancer survivors: implications for developing community support services , 2008, Psycho-oncology.

[111]  F. Mayer,et al.  Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  Trevor Murrells,et al.  Patients' supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  C. K. Khoo,et al.  A Prospective Randomized Controlled Trial of Multimodal Perioperative Management Protocol in Patients Undergoing Elective Colorectal Resection for Cancer , 2007, Annals of surgery.

[114]  F. Shepherd,et al.  Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[115]  A. Oza,et al.  Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer , 2007, Cancer.

[116]  M. Gore,et al.  Intraperitoneal chemotherapy in ovarian cancer remains experimental. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  V. Torri,et al.  Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis , 2006, British Journal of Cancer.

[118]  F. Couch,et al.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. , 2006, JAMA.

[119]  R. Barakat,et al.  Fallopian Tube Cancer , 2006 .

[120]  J. Ledermann,et al.  Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. , 2006, Gynecologic oncology.

[121]  N. Hacker,et al.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. , 2005, Journal of the National Cancer Institute.

[122]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[123]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[124]  C. Gilks,et al.  Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. , 2004, Human pathology.

[125]  P. Neven,et al.  Endometriosis and the development of malignant tumours of the pelvis. A review of literature. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[126]  T. Motoyama,et al.  Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[127]  F. Amant,et al.  Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. , 2003, Gynecologic oncology.

[128]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[129]  M. Franchi,et al.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. , 2003, Journal of the National Cancer Institute.

[130]  M. Parmar,et al.  International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. , 2003, Journal of the National Cancer Institute.

[131]  M. Parmar,et al.  International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma. , 2003, Journal of the National Cancer Institute.

[132]  R. Mannel,et al.  Ascites as a predictor of ovarian malignancy. , 2002, Gynecologic oncology.

[133]  S. Pecorelli,et al.  Interval debulking surgery in advanced epithelial ovarian cancer. , 2002, Best practice & research. Clinical obstetrics & gynaecology.

[134]  M. Johnston,et al.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.

[135]  R. Kurman,et al.  Refined Diagnostic Criteria for Implants Associated With Ovarian Atypical Proliferative Serous Tumors (Borderline) and Micropapillary Serous Carcinomas , 2001, The American journal of surgical pathology.

[136]  R. Scully,et al.  Mucinous Tumors of the Ovary: A Clinicopathologic Study of 196 Borderline Tumors (of Intestinal Type) and Carcinomas, Including an Evaluation of 11 Cases With `Pseudomyxoma Peritonei' , 2000, The American journal of surgical pathology.

[137]  T. Yamada,et al.  Lymph node metastasis in stage I epithelial ovarian cancer. , 2000, Gynecologic oncology.

[138]  D. Luesley.  Improving outcomes in gynaecological cancers , 2000, BJOG : an international journal of obstetrics and gynaecology.

[139]  R. Kurman,et al.  Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. , 2000, Human pathology.

[140]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[141]  W. Gregory,et al.  A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[142]  D. Gershenson,et al.  Unusual features of serous neoplasms of low malignant potential during pregnancy. , 1997, Gynecologic oncology.

[143]  W. R. Hart,et al.  Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. , 1995, The American journal of surgical pathology.

[144]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[145]  E. Oliva,et al.  Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Clinicopathological Analysis of 150 Cases , 1994, The American journal of surgical pathology.

[146]  D. Oram,et al.  A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.

[147]  C. Redman,et al.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.

[148]  E. Unger,et al.  Synchronous carcinomas of the uterine corpus and ovary. , 1984, Gynecologic oncology.

[149]  S. Kjaer,et al.  A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. , 2017, Gynecologic oncology.

[150]  A. Reuss,et al.  Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. , 2016, The Lancet. Oncology.

[151]  C. Preibisch,et al.  Bladder Management With Epidural Anesthesia During Labor: A Randomized Controlled Trial , 2015, MCN. The American journal of maternal child nursing.

[152]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[153]  I. Floriani,et al.  Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  I. Jacobs,et al.  Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  H. Kitchener,et al.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. , 2012, The Cochrane database of systematic reviews.

[156]  J. Dungan.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2012 .

[157]  A. Degnim.  Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality , 2011 .

[158]  Gang Shi,et al.  Perioperative enhanced recovery programmes for gynaecological cancer patients. , 2010, The Cochrane database of systematic reviews.

[159]  M. Fitch,et al.  Identifying supportive care needs of women with ovarian cancer. , 2010, Canadian oncology nursing journal = Revue canadienne de nursing oncologique.

[160]  P. Loehrer.  Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation , 2008 .

[161]  W. Cliby,et al.  Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. , 2006, Gynecologic oncology.

[162]  N. Johnson,et al.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. , 2006, The Cochrane database of systematic reviews.

[163]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[164]  M. Parmar,et al.  International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. , 2003, Journal of the National Cancer Institute.

[165]  B. Karlan,et al.  Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. , 2001, Gynecologic oncology.

[166]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.

[167]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.